Home / Health / Millions Face ADHD Med Shortage: Supply Chain Woes Persist
Millions Face ADHD Med Shortage: Supply Chain Woes Persist
26 Mar
Summary
- ADHD medication shortages persist into another year for millions.
- Global supply chain disruptions and manufacturing slowdowns cause shortages.
- Federal production caps by the DEA may hinder increased supply.
Americans relying on ADHD medications are experiencing prolonged prescription difficulties, with shortages of key stimulant drugs now entering another year. These ongoing issues are linked to deeper structural weaknesses within the U.S. pharmaceutical supply chain, according to research cited by CIDRAP.
Global supply chain disruptions, originating during the COVID-19 pandemic and not yet fully resolved, have impacted the availability of active pharmaceutical ingredients. Manufacturing slowdowns and a lack of supply chain resilience, characterized by a high dependency on single facilities for active pharmaceutical ingredients, contribute to persistent shortages.
Compounding these problems are federal production caps imposed by the DEA on stimulant medications. These quotas, designed to prevent misuse, may not adequately respond to rising legitimate medical demand. Increased diagnosis and telehealth access have driven demand, but supply has not kept pace, leaving millions with impaired concentration and productivity.
